MANAGEMENT OF SICKLE CELL VASO-0CCLUSIVE EPISODES

镰状细胞 VASO-0 闭塞性发作的处理

• 批准号: 6667541
• 负责人: KAREN A KALINYAK
• 金额: $ 22.86万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6667541
• 关键词: African American; analgesia; behavioral /social science research tag; blood vessel occlusion; caregivers; clinical research; clinical trials; drug screening /evaluation; family; health behavior; health education; human subject; methylphenidate; middle childhood (6-11); pain; patient care management; sickle cell crisis; spirometry

Vaso-occlusive (VOC) episodes represent the major source of morbidity and impairment for patients with sickle cell disease (SCD), and the management of pain is a continued challenge to patients, families, and health care providers. There is little consensus among medical care providers about the optimal pharmacological and non-pharmacological approaches to SCD pain management. In addition, VOC episodes and its medical management can produce physiological and pharmacological sequelae which can be detrimental to the patients. Conversely, optimal management of the VOC episodes is likely to have short-term as well as long term benefits of the patient. This program consists of three integrated clinical research studies which address the optimal management of VOC episodes from psychological, pharmacological and physiological perspectives. The three specific aims of this project are: 1) to conduct a randomized clinical trial to test the efficacy of a family-based pain management program designed to teach pediatric patients with SCD and their primary caregivers how to optimally control pain by using a combination of pharmacological and non-pharmacological strategies; 2) to conduct a double-blind randomized clinical trial to determine the benefits and risks of adjuvant use of methylphenidate in the treatment of severe VOC pain in hospitalized patients; and 3) to conduct a randomized trail of the outpatient use of the incentive spirometer during vaso-occlusive episodes to determine if its use this setting will prevent the development of the acute chest syndrome (ACS).

血管熟悉（VOC）发作代表了发病率的主要来源 镰状细胞疾病（SCD）患者和管理的损害 疼痛是对患者，家庭和医疗保健的持续挑战 提供者。医疗服务提供者之间几乎没有共识 SCD疼痛的最佳药理和非药理学方法 管理。此外，VOC情节及其医疗管理可以 产生生理和药理学后遗症 对患者有害。相反，VOC的最佳管理 情节可能具有短期和长期的好处 病人。该计划由三项综合临床研究组成 研究涉及VOC情节的最佳管理 心理，药理和生理观点。 该项目的三个具体目的是：1）进行随机 临床试验测试家庭疼痛管理的功效 旨在教SCD及其主要儿科患者的计划 护理人员如何通过组合使用 药理和非药理策略； 2）进行 双盲随机临床试验以确定收益和风险 在治疗严重VOC疼痛的辅助使用辅助使用 住院的患者； 3）进行一条随机步道 在血管结合发作期间，奖励肺活量计的门诊儿使用 为了确定其使用是否会阻止 急性胸部综合征（ACS）。